Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Daromun |
| Trade Name | |
| Synonyms | L19-IL2/L19-TNF-alpha|Darleukin/Fibromun|L19IL2/L19TNF |
| Drug Descriptions |
Daromun consists of a mixture of darleukin, a recombinant IL2 linked to the fibronectin extra domain B (EDB) targeting single-chain variable fragment (L19), and fibromun, a human TNF-alpha linked to L19, which binds to cells expressing fibronectin EDB in tumor neovasculature, potentially resulting in the induction of antitumor immune response against tumor cells expressing EDB-containing fibronectin (NCI Drug Dictionary). |
| DrugClasses | |
| CAS Registry Number | NA |
| NCIT ID | C154627 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Daromun | Daromun | 0 | 3 |
| Daromun + Lomustine | Daromun Lomustine | 0 | 0 |
| Daromun + Onfekafusp alfa | Daromun Onfekafusp alfa | 0 | 1 |
| Daromun + Pembrolizumab | Daromun Pembrolizumab | 0 | 1 |